{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T14:20:29Z","timestamp":1792592429505,"version":"4.5.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,8,17]]},"DOI":"10.7759\/cureus.43635","type":"journal-article","created":{"date-parts":[[2023,8,17]],"date-time":"2023-08-17T14:05:37Z","timestamp":1692281137000},"source":"Crossref","is-referenced-by-count":14,"title":["Vitamin E and Pioglitazone: A Comprehensive Systematic Review of Their Efficacy in Non-alcoholic Fatty Liver Disease"],"prefix":"10.7759","author":[{"given":"Iqra J","family":"Mazhar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed","family":"Yasir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saba","family":"Sarfraz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gandhala","family":"Shlaghya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sri Harsha","family":"Narayana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ujala","family":"Mushtaq","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Basim","family":"Shaman Ameen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuhao","family":"Nie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Nechi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sai Sri","family":"Penumetcha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1002\/cld.1045","article-title":"Nonalcoholic fatty liver disease and recent guideline updates","volume":"17","author":"Ando Y","year":"2021","unstructured":"Ando Y, Jou JH. Nonalcoholic fatty liver disease and recent guideline updates. Clin Liver Dis (Hoboken). 2021, 17:23-8. 10.1002\/cld.1045","journal-title":"Clin Liver Dis (Hoboken)"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1186\/s12902-022-00980-1","article-title":"Non-alcoholic fatty liver disease (NAFLD): a review of pathophysiology, clinical management and effects of weight loss","volume":"22","author":"Pouwels S","year":"2022","unstructured":"Pouwels S, Sakran N, Graham Y, et al.. Non-alcoholic fatty liver disease (NAFLD): a review of pathophysiology, clinical management and effects of weight loss. BMC Endocr Disord. 2022, 22:63. 10.1186\/s12902-022-00980-1","journal-title":"BMC Endocr Disord"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.3390\/ijerph18105227","article-title":"Non-alcoholic fatty liver disease: metabolic, genetic, epigenetic and environmental risk factors","volume":"18","author":"Juanola O","year":"2021","unstructured":"Juanola O, Mart\u00ednez-L\u00f3pez S, Franc\u00e9s R, G\u00f3mez-Hurtado I. Non-alcoholic fatty liver disease: metabolic, genetic, epigenetic and environmental risk factors. Int J Environ Res Public Health. 2021, 18:5227. 10.3390\/ijerph18105227","journal-title":"Int J Environ Res Public Health"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v26.i39.5919","article-title":"Clinical assessment and management of liver fibrosis in non-alcoholic fatty liver disease","volume":"26","author":"Campos-Murgu\u00eda A","year":"2020","unstructured":"Campos-Murgu\u00eda A, Ruiz-Marg\u00e1in A, Gonz\u00e1lez-Regueiro JA, Mac\u00edas-Rodr\u00edguez RU. Clinical assessment and management of liver fibrosis in non-alcoholic fatty liver disease. World J Gastroenterol. 2020, 26:5919-43. 10.3748\/wjg.v26.i39.5919","journal-title":"World J Gastroenterol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2023.1147458","article-title":"Non-alcoholic fatty liver disease and incidence of microvascular complications of diabetes in patients with type 2 diabetes: a prospective cohort study","volume":"14","author":"Deravi N","year":"2023","unstructured":"Deravi N, Dehghani Firouzabadi F, Moosaie F, et al.. Non-alcoholic fatty liver disease and incidence of microvascular complications of diabetes in patients with type 2 diabetes: a prospective cohort study. Front Endocrinol (Lausanne). 2023, 14:1147458. 10.3389\/fendo.2023.1147458","journal-title":"Front Endocrinol (Lausanne)"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1155\/2020\/3920196","article-title":"The intricate relationship between type 2 diabetes mellitus (T2DM), insulin resistance (IR), and nonalcoholic fatty liver disease (NAFLD)","volume":"2020","author":"Tanase DM","year":"2020","unstructured":"Tanase DM, Gosav EM, Costea CF, et al.. The intricate relationship between type 2 diabetes mellitus (T2DM), insulin resistance (IR), and nonalcoholic fatty liver disease (NAFLD). J Diabetes Res. 2020, 2020:3920196. 10.1155\/2020\/3920196","journal-title":"J Diabetes Res"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.redox.2021.101937","article-title":"Impact of vitamin E on redox biomarkers in non-alcoholic fatty liver disease","volume":"42","author":"Podszun MC","year":"2021","unstructured":"Podszun MC, Frank J. Impact of vitamin E on redox biomarkers in non-alcoholic fatty liver disease. Redox Biol. 2021, 42:101937. 10.1016\/j.redox.2021.101937","journal-title":"Redox Biol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1159\/000443344","article-title":"EASL-EASD-EASO clinical practice guidelines for the management of non-alcoholic fatty liver disease","volume":"9","year":"2016","unstructured":"EASL-EASD-EASO clinical practice guidelines for the management of non-alcoholic fatty liver disease. Obes Facts. 2016, 9.65-90. 10.1159\/000443344","journal-title":"Obes Facts"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.3390\/medicina55050166","article-title":"Dietary and pharmacological treatment of nonalcoholic fatty liver disease","volume":"55","author":"Jeznach-Steinhagen A","year":"2019","unstructured":"Jeznach-Steinhagen A, Ostrowska J, Czerwonogrodzka-Senczyna A, Boniecka I, Shahnazaryan U, Kury\u0142owicz A. Dietary and pharmacological treatment of nonalcoholic fatty liver disease. Medicina (Kaunas). 2019, 55:166. 10.3390\/medicina55050166","journal-title":"Medicina (Kaunas)"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n160","article-title":"PRISMA 2020 explanation and elaboration: updated guidance and exemplars for reporting systematic reviews","volume":"372","author":"Page MJ","year":"2021","unstructured":"Page MJ, Moher D, Bossuyt PM, et al.. PRISMA 2020 explanation and elaboration: updated guidance and exemplars for reporting systematic reviews. BMJ. 2021, 372:n160. 10.1136\/bmj.n160","journal-title":"BMJ"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne JA","year":"2019","unstructured":"Sterne JA, Savovi\u0107 J, Page MJ, et al.. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019, 366:l4898. 10.1136\/bmj.l4898","journal-title":"BMJ"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1186\/s41073-019-0064-8","article-title":"SANRA-a scale for the quality assessment of narrative review articles","volume":"4","author":"Baethge C","year":"2019","unstructured":"Baethge C, Goldbeck-Wood S, Mertens S. SANRA-a scale for the quality assessment of narrative review articles. Res Integr Peer Rev. 2019, 4:5. 10.1186\/s41073-019-0064-8","journal-title":"Res Integr Peer Rev"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.26355\/eurrev_202112_27442","article-title":"A randomized controlled trial comparing the effects of vitamin E, ursodeoxycholic acid and pentoxifylline on Egyptian non-alcoholic steatohepatitis patients","volume":"25","author":"Fouda A","year":"2021","unstructured":"Fouda A, Abdelaziz AE, Hussien M, Ali AA, Abdelkawy KS, Elbarbry F. A randomized controlled trial comparing the effects of vitamin E, ursodeoxycholic acid and pentoxifylline on Egyptian non-alcoholic steatohepatitis patients. Eur Rev Med Pharmacol Sci. 2021, 25:7449-59. 10.26355\/eurrev_202112_27442","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1002\/iub.1991","article-title":"Role of vitamin E in nonalcoholic fatty liver disease","volume":"71","author":"Nagashimada M","year":"2019","unstructured":"Nagashimada M, Ota T. Role of vitamin E in nonalcoholic fatty liver disease. IUBMB Life. 2019, 71:516-22. 10.1002\/iub.1991","journal-title":"IUBMB Life"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1136\/bmjdrc-2020-001990","article-title":"Comparing the effects of tofogliflozin and pioglitazone in non-alcoholic fatty liver disease patients with type 2 diabetes mellitus (ToPiND study): a randomized prospective open-label controlled trial","volume":"9","author":"Yoneda M","year":"2021","unstructured":"Yoneda M, Honda Y, Ogawa Y, et al.. Comparing the effects of tofogliflozin and pioglitazone in non-alcoholic fatty liver disease patients with type 2 diabetes mellitus (ToPiND study): a randomized prospective open-label controlled trial. BMJ Open Diabetes Res Care. 2021, 9:e001990. 10.1136\/bmjdrc-2020-001990","journal-title":"BMJ Open Diabetes Res Care"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1002\/hep4.1993","article-title":"Combination of tofogliflozin and pioglitazone for NAFLD: extension to the ToPiND randomized controlled trial","volume":"6","author":"Yoneda M","year":"2022","unstructured":"Yoneda M, Kobayashi T, Honda Y, et al.. Combination of tofogliflozin and pioglitazone for NAFLD: extension to the ToPiND randomized controlled trial. Hepatol Commun. 2022, 6:2273-85. 10.1002\/hep4.1993","journal-title":"Hepatol Commun"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1186\/s13293-020-00344-1","article-title":"Gender differences in the efficacy of pioglitazone treatment in nonalcoholic fatty liver disease patients with abnormal glucose metabolism","volume":"12","author":"Yan H","year":"2021","unstructured":"Yan H, Wu W, Chang X, Xia M, Ma S, Wang L, Gao J. Gender differences in the efficacy of pioglitazone treatment in nonalcoholic fatty liver disease patients with abnormal glucose metabolism. Biol Sex Differ. 2021, 12:1. 10.1186\/s13293-020-00344-1","journal-title":"Biol Sex Differ"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1111\/jdi.13279","article-title":"Comparison of the effects of three kinds of glucose-lowering drugs on non-alcoholic fatty liver disease in patients with type 2 diabetes: a randomized, open-label, three-arm, active control study","volume":"11","author":"Kinoshita T","year":"2020","unstructured":"Kinoshita T, Shimoda M, Nakashima K, et al.. Comparison of the effects of three kinds of glucose-lowering drugs on non-alcoholic fatty liver disease in patients with type 2 diabetes: a randomized, open-label, three-arm, active control study. J Diabetes Investig. 2020, 11:1612-22. 10.1111\/jdi.13279","journal-title":"J Diabetes Investig"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2021.615409","article-title":"Pioglitazone for NAFLD patients with prediabetes or type 2 diabetes mellitus: a meta-analysis","volume":"12","author":"Lian J","year":"2021","unstructured":"Lian J, Fu J. Pioglitazone for NAFLD patients with prediabetes or type 2 diabetes mellitus: a meta-analysis. Front Endocrinol (Lausanne). 2021, 12:615409. 10.3389\/fendo.2021.615409","journal-title":"Front Endocrinol (Lausanne)"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2021.649018","article-title":"Efficacy of various hypoglycemic agents in the treatment of patients with nonalcoholic liver disease with or without diabetes: a network meta-analysis","volume":"12","author":"Lian J","year":"2021","unstructured":"Lian J, Fu J. Efficacy of various hypoglycemic agents in the treatment of patients with nonalcoholic liver disease with or without diabetes: a network meta-analysis. Front Endocrinol (Lausanne). 2021, 12:649018. 10.3389\/fendo.2021.649018","journal-title":"Front Endocrinol (Lausanne)"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1111\/dom.14304","article-title":"Pioglitazone and bariatric surgery are the most effective treatments for non-alcoholic steatohepatitis: a hierarchical network meta-analysis","volume":"23","author":"Panunzi S","year":"2021","unstructured":"Panunzi S, Maltese S, Verrastro O, et al.. Pioglitazone and bariatric surgery are the most effective treatments for non-alcoholic steatohepatitis: a hierarchical network meta-analysis. Diabetes Obes Metab. 2021, 23:980-90. 10.1111\/dom.14304","journal-title":"Diabetes Obes Metab"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000031508","article-title":"Pioglitazone on nonalcoholic steatohepatitis: a systematic review and meta-analysis of 15 RCTs","volume":"101","author":"Zhao Y","year":"2022","unstructured":"Zhao Y, Zhao W, Wang H, Zhao Y, Bu H, Takahashi H. Pioglitazone on nonalcoholic steatohepatitis: a systematic review and meta-analysis of 15 RCTs. Medicine (Baltimore). 2022, 101:e31508. 10.1097\/MD.0000000000031508","journal-title":"Medicine (Baltimore)"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.3350\/cmh.2022.0015","article-title":"Old and new classes of glucose-lowering agents as treatments for non-alcoholic fatty liver disease: a narrative review","volume":"28","author":"Miao L","year":"2022","unstructured":"Miao L, Xu J, Targher G, Byrne CD, Zheng MH. Old and new classes of glucose-lowering agents as treatments for non-alcoholic fatty liver disease: a narrative review. Clin Mol Hepatol. 2022, 28:725-38. 10.3350\/cmh.2022.0015","journal-title":"Clin Mol Hepatol"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1007\/s10620-021-07206-9","article-title":"A review of the epidemiology, pathophysiology, and efficacy of anti-diabetic drugs used in the treatment of nonalcoholic fatty liver disease","volume":"66","author":"Manka PP","year":"2021","unstructured":"Manka PP, Kaya E, Canbay A, Syn WK. A review of the epidemiology, pathophysiology, and efficacy of anti-diabetic drugs used in the treatment of nonalcoholic fatty liver disease. Dig Dis Sci. 2021, 66:3676-88. 10.1007\/s10620-021-07206-9","journal-title":"Dig Dis Sci"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.3350\/cmh.2020.0137","article-title":"Beneficial effect of anti-diabetic drugs for nonalcoholic fatty liver disease","volume":"26","author":"Kim KS","year":"2020","unstructured":"Kim KS, Lee BW. Beneficial effect of anti-diabetic drugs for nonalcoholic fatty liver disease. Clin Mol Hepatol. 2020, 26:430-43. 10.3350\/cmh.2020.0137","journal-title":"Clin Mol Hepatol"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1111\/apt.16583","article-title":"Systematic review with network meta-analysis: comparative efficacy of pharmacologic therapies for fibrosis improvement and resolution of NASH","volume":"54","author":"Majzoub AM","year":"2021","unstructured":"Majzoub AM, Nayfeh T, Barnard A, et al.. Systematic review with network meta-analysis: comparative efficacy of pharmacologic therapies for fibrosis improvement and resolution of NASH. Aliment Pharmacol Ther. 2021, 54:880-9. 10.1111\/apt.16583","journal-title":"Aliment Pharmacol Ther"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.3390\/ijerph16224334","article-title":"Pharmacological therapy of non-alcoholic fatty liver disease: what drugs are available now and future perspectives","volume":"16","author":"Pennisi G","year":"2019","unstructured":"Pennisi G, Celsa C, Spatola F, Dallio M, Federico A, Petta S. Pharmacological therapy of non-alcoholic fatty liver disease: what drugs are available now and future perspectives. Int J Environ Res Public Health. 2019, 16:4334. 10.3390\/ijerph16224334","journal-title":"Int J Environ Res Public Health"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22052350","article-title":"Treatments for NAFLD: state of art","volume":"22","author":"Mantovani A","year":"2021","unstructured":"Mantovani A, Dalbeni A. Treatments for NAFLD: state of art. Int J Mol Sci. 2021, 22:2350. 10.3390\/ijms22052350","journal-title":"Int J Mol Sci"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1111\/joim.13531","article-title":"Current treatment of non-alcoholic fatty liver disease","volume":"292","author":"Paternostro R","year":"2022","unstructured":"Paternostro R, Trauner M. Current treatment of non-alcoholic fatty liver disease. J Intern Med. 2022, 292:190-204. 10.1111\/joim.13531","journal-title":"J Intern Med"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1186\/s13643-019-1200-8","article-title":"Diabetes drugs for nonalcoholic fatty liver disease: a systematic review","volume":"8","author":"Blazina I","year":"2019","unstructured":"Blazina I, Selph S. Diabetes drugs for nonalcoholic fatty liver disease: a systematic review. Syst Rev. 2019, 8:295. 10.1186\/s13643-019-1200-8","journal-title":"Syst Rev"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-019-00898-6","article-title":"Pharmacological treatment for non-alcoholic fatty liver disease","volume":"36","author":"Francque S","year":"2019","unstructured":"Francque S, Vonghia L. Pharmacological treatment for non-alcoholic fatty liver disease. Adv Ther. 2019, 36:1052-74. 10.1007\/s12325-019-00898-6","journal-title":"Adv Ther"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.3727\/105221619X15536120524171","article-title":"Current and emerging approaches for nonalcoholic steatohepatitis treatment","volume":"19","author":"Chen MM","year":"2019","unstructured":"Chen MM, Cai JJ, Yu Y, She ZG, Li H. Current and emerging approaches for nonalcoholic steatohepatitis treatment. Gene Expr. 2019, 19:175-85. 10.3727\/105221619X15536120524171","journal-title":"Gene Expr"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.3350\/cmh.2022.0186","article-title":"Therapeutic mechanisms and beneficial effects of non-antidiabetic drugs in chronic liver diseases","volume":"28","author":"Lee HA","year":"2022","unstructured":"Lee HA, Chang Y, Sung PS, et al.. Therapeutic mechanisms and beneficial effects of non-antidiabetic drugs in chronic liver diseases. Clin Mol Hepatol. 2022, 28:425-72. 10.3350\/cmh.2022.0186","journal-title":"Clin Mol Hepatol"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1016\/j.cct.2008.09.003","article-title":"Pioglitazone versus vitamin E versus placebo for the treatment of non-diabetic patients with non-alcoholic steatohepatitis: PIVENS trial design","volume":"30","author":"Chalasani NP","year":"2009","unstructured":"Chalasani NP, Sanyal AJ, Kowdley KV, et al.. Pioglitazone versus vitamin E versus placebo for the treatment of non-diabetic patients with non-alcoholic steatohepatitis: PIVENS trial design. Contemp Clin Trials. 2009, 30:88-96. 10.1016\/j.cct.2008.09.003","journal-title":"Contemp Clin Trials"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/168872-vitamin-e-and-pioglitazone-a-comprehensive-systematic-review-of-their-efficacy-in-non-alcoholic-fatty-liver-disease","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T20:04:28Z","timestamp":1707509068000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/168872-vitamin-e-and-pioglitazone-a-comprehensive-systematic-review-of-their-efficacy-in-non-alcoholic-fatty-liver-disease"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,17]]},"references-count":34,"URL":"https:\/\/doi.org\/10.7759\/cureus.43635","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2023,8,17]]}}}